BioNTech confirmed ECï¾’s proposal to purchase additional doses of vaccine
On Jan. 8, 2021, BioNTech announced that it was in talks with the European Commission (EC) about an…
Oragenics entered into material transfer agreement with adjuvance technologies for COVID-19 vaccine adjuvant
On Jan. 7, 2021, Oragenics announced entering into a material transfer agreement with Adjuvance Technologies for use of…
Novavax finalized agreement with Commonwealth of Australia for 51 million doses of COVID-19 vaccine
On Jan. 7, 2021, Novavax announced that it had executed an Advance Purchase Agreement with the Commonwealth of…
Labcorp awarded CDC contract to study variants of COVID-19 virus and improve public health response
On Jan. 7, 2021, LabCorp announced that it had been awarded a contract from the Centers for Disease…
HHS announced $22 billion in funding to support expanded testing, vaccination distribution
On Jan. 6, 2021, the U.S. Department of Health and Human Services (HHS) announced the Centers for Disease…
Protective immunity against SARS-CoV-2 could last eight months or more
On Jan. 6, 2021, the La Jolla Institute for Immunology announced data that suggest nearly all COVID-19 survivors…
European Commission authorized COVID-19 vaccine Moderna in Europe
On Jan. 6, 2021, Moderna announced that the European Commission had granted a conditional marketing authorization for COVID-19…
CureVac and Bayer joined forces on COVID-19 vaccine candidate CVnCoV
On Jan. 6, 2021, Bayer announced it had signed a collaboration and services agreement with CureVac, a biopharmaceutical…
Large clinical trial tested combination monoclonal antibody therapy for mild/moderate COVID-19
On Jan. 5, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announed that a phase 2/3…
Illumina and Helix collaborated to assess prevalence of New SARS-CoV-2 UK variant (B117) in the U.S.
On Jan. 5, 2021, Illumina and Helix announced a collaboration to augment national surveillance infrastructure in the U.S….
AIM ImmunoTech announced first COVID-19-induced chronic fatigue ﾓLong Haulerﾔ patient dosed with Ampligen
On Jan. 5, 2021, AIM ImmunoTech announced that the active AMP-511 Expanded Access Program (EAP) had dosed its…
FDA announced statement on authorized dosing schedules for COVID-19 vaccines
On Jan. 4, 2021, the FDA announced that the two different mRNA vaccines were shown remarkable effectiveness of…
First evidence of UK coronavirus variant in California confirmed by Scripps Research lab
On Jan. 4, 2021, a research partnership between scientists at Scripps Research and UC San Diego found the…
Moderna provided COVID-19 vaccine supply update
On Jan. 4, 2021, Moderna announced a supply update for the Moderna COVID-19 Vaccine, increasing its base-case global…
Israeli Ministry of Health authorized COVID-19 Vaccine Moderna for use in Israel
On Jan. 4, 2021, Moderna announced that Israelï¾’s Ministry of Health (MOH) had given authorization to import the…
INOVIO and Advaccine announced partnership to commercialize COVID-19 DNA vaccine candidate in China
On Jan. 4, 2021, Inovio Pharmaceuticals and Advaccine Biopharmaceuticals announced that they had entered into a collaboration and…
Biotechnology | COVID-19 | Life Science News | Vaccine | WHO
WHO issued its first EUV for a COVID-19 vaccine and emphasized need for equitable global access
On Dec. 31, 2020, the World Health Organization (WHO) listed the Comirnaty COVID-19 mRNA vaccine for emergency use,…
Moderna confirmed 40 million COVID-19 vaccine dose supply agreement with Republic of Korea
On Dec. 31, 2020, Moderna confirmed it had entered into a supply agreement with the government of the…
CytoDyn research on critically Ill COVID-19 patients published in Journal of Translational Autoimmunity
On Dec. 31, 2020, CytoDyn announced a research manuscript submitted by Nicholas J. Agresti, M.D. had been accepted…
Recipharm and Moderna finalized agreement for aseptic drug manufacturing and fill-finish for countries outside the US
On Dec. 30, 2020, Moderna announced that they had reached an agreement to support formulation and fill-finish a…
Bausch Health’s DEXAVEN received new indication in Poland to treat patients with SARS-CoV-2
On Dec. 30, 2020, Bausch Health announced that the Office for Registration of Medicinal Products, Medical Devices and…
NIH study uncovered blood vessel damage and inflammation in COVID-19 patientsï¾’ brains but no infection
On Dec. 30, 2020, the NIH researchers announced that an in-depth study of how COVID-19 affects a patientï¾’s…
Peer-reviewed report on Moderna COVID-19 vaccine published
On Dec. 30, 2020, the NIH announced that the investigational vaccine known as mRNA-1273 was 94.1% efficacious in…
Biotechnology | COVID-19 | FDA | Life Science News | NIH | Therapeutics
Medigen Vaccines obtained TFDA phase 2 IND approval for COVID19 vaccine
On Dec. 30, 2020, Medigen Vaccine Biologics announced that it had obtained TFDA Phase 2 IND approval of…
UK medicines regulator approved Oxford University/AstraZeneca COVID-19 vaccine
On Dec. 30, 2020, the COVID-19 vaccine developed by Oxford University/AstraZeneca was given regulatory approval by the UK…
Mateon global study for OT-101/ TGF-inhibitor against COVID-19 treated its first patient
On Dec. 30, 2020, Mateon Therapeutics announced that it had enrolled and treated its first sentinel Part 1…
Emergent and Mount Sinai Health System announced clinical program to evuate COVID-HIG product candidate
On Dec. 29, 2020, Emergent BioSolutions and Mount Sinai Health System announced initiation of the clinical program to…
Moderna confirmed discussions with government of South Korea to supply 40 million doses of COVID-19 vaccine
On Dec. 29, 2020, Moderna confirmed that the Company was engaged in discussions with the government of South…
UNMC participated in COVID-19 vaccine study, planned to enroll 1,000
On Dec. 29, 2020, University of Nebraska Medical Center (UNMC) and Nebraska Medicine announced participation in a clinical…
Regeneron announced encouraging data from COVID-19 antibody cocktail trial in hospitalized patient
On Dec. 29, 2020, Regeneron announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the…